GHRP-6 and CJC-1295 are another classic growth-hormone peptide pairing rather than a true rivalry, because they act on different, complementary receptors. GHRP-6 is a GHRP (ghrelin-receptor agonist) that triggers a GH pulse and strongly increases appetite; CJC-1295 is a GHRH analog that amplifies the pulse. Neither is approved; both are banned in sport.
At a glance
| GHRP-6 | CJC-1295 | |
|---|---|---|
| Class | GHRP (ghrelin-receptor agonist) | GHRH analog |
| Mechanism | Triggers a GH pulse | Increases GH pulse amplitude/duration |
| Appetite effect | Strong increase | Minimal |
| Often used | Paired with a GHRH analog | Paired with a GHRP |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
The bottom line
Bottom line: Like ipamorelin + CJC-1295, this is a GHRP-plus-GHRH combination — two halves of the GH-release system rather than competitors. GHRP-6 adds strong appetite stimulation that ipamorelin lacks. Neither is approved, human outcome data are limited, and both are prohibited in sport.
Frequently asked questions
Why are GHRP-6 and CJC-1295 used together?
They act on complementary receptors — GHRP-6 on the ghrelin receptor and CJC-1295 on the GHRH receptor — so combining them can produce a larger growth-hormone response than either alone. Human evidence is limited.
What's the main side effect of GHRP-6?
GHRP-6 is well known for strongly increasing appetite. CJC-1295, a GHRH analog, does not have this effect. Neither is FDA-approved.
Are they legal in sport?
No. Growth-hormone secretagogues like GHRP-6 and GHRH analogs like CJC-1295 are banned at all times under the World Anti-Doping Agency code.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. Peer-reviewed study
- Frago LM, Paneda C, Argente J, Chowen JA. GHRP-6 increases IGF-I mRNA and activates Akt in RCA-6 cells. J Neuroendocrinol. 2005. Peer-reviewed study
- Pombo M, Leal-Cerro A, Barreiro J, et al. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J Pediatr Endocrinol Metab. 1996. Peer-reviewed study
- Zhao X, Pan K, Li R, et al. Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. J Nanobiotechnology. 2025. Peer-reviewed study
- Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024. Peer-reviewed study
- Yu AP, Pei XM, Sin TK, et al. [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle. Mol Cell Endocrinol. 2015. Peer-reviewed study
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. Peer-reviewed study
- Jette L, Leger R, Thibaudeau K, et al. hGRF(1-29)-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. Peer-reviewed study
- Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019. Peer-reviewed study
- Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016. Peer-reviewed study
- Timms M, Ganio K, Forbes G, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019. Peer-reviewed study
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. Peer-reviewed study